Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland.

Hai L, Szwarc MM, Lonard DM, Rajapakshe K, Perera D, Coarfa C, Ittmann M, Fernandez-Valdivia R, Lydon JP.

Cytokine. 2019 Nov;123:154745. doi: 10.1016/j.cyto.2019.154745. Epub 2019 Jun 18.

PMID:
31226438
2.

SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.

Song X, Chen H, Zhang C, Yu Y, Chen Z, Liang H, Van Buren G 2nd, McElhany AL, Fisher WE, Lonard DM, O'Malley BW, Wang J.

Cancer Lett. 2019 Feb 1;442:310-319. doi: 10.1016/j.canlet.2018.11.012. Epub 2018 Nov 10.

PMID:
30423406
3.

SRC-3 Coactivator Governs Dynamic Estrogen-Induced Chromatin Looping Interactions during Transcription.

Panigrahi AK, Foulds CE, Lanz RB, Hamilton RA, Yi P, Lonard DM, Tsai MJ, Tsai SY, O'Malley BW.

Mol Cell. 2018 May 17;70(4):679-694.e7. doi: 10.1016/j.molcel.2018.04.014.

4.

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.

Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, Yu Y, Lonard DM, Wang J, Wang SP, Edwards DG, Lavere PF, Shao J, Yi P, Jain A, Jung SY, Malovannaya A, Li S, Shao J, Roeder RG, Ellis MJ, Qin J, Fuqua SAW, O'Malley BW, Foulds CE.

Oncogene. 2018 Aug;37(33):4581-4598. doi: 10.1038/s41388-018-0284-2. Epub 2018 May 11.

5.

USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.

Padmanabhan A, Candelaria N, Wong KK, Nikolai BC, Lonard DM, O'Malley BW, Richards JS.

Nat Commun. 2018 Mar 28;9(1):1270. doi: 10.1038/s41467-018-03599-w.

6.

Uterine function in the mouse requires speckle-type poz protein.

Hai L, Szwarc MM, He B, Lonard DM, Kommagani R, DeMayo FJ, Lydon JP.

Biol Reprod. 2018 Jun 1;98(6):856-869. doi: 10.1093/biolre/ioy060.

7.

Human endometrial stromal cell decidualization requires transcriptional reprogramming by PLZF.

Szwarc MM, Hai L, Gibbons WE, Peavey MC, White LD, Mo Q, Lonard DM, Kommagani R, Lanz RB, DeMayo FJ, Lydon JP.

Biol Reprod. 2018 Jan 1;98(1):15-27. doi: 10.1093/biolre/iox161.

8.

Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells.

Rohira AD, Yan F, Wang L, Wang J, Zhou S, Lu A, Yu Y, Xu J, Lonard DM, O'Malley BW.

Cancer Res. 2017 Aug 15;77(16):4293-4304. doi: 10.1158/0008-5472.CAN-16-2982. Epub 2017 Jun 13.

9.

Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers.

Rohira AD, Lonard DM.

Biochem Pharmacol. 2017 Sep 15;140:1-7. doi: 10.1016/j.bcp.2017.04.005. Epub 2017 Apr 6. Review.

PMID:
28390937
10.

A bioluminescence reporter mouse that monitors expression of constitutively active β-catenin.

Szwarc MM, Kommagani R, Peavey MC, Hai L, Lonard DM, Lydon JP.

PLoS One. 2017 Mar 2;12(3):e0173014. doi: 10.1371/journal.pone.0173014. eCollection 2017.

11.

Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer.

Lonard DM, O'Malley BW.

Clin Cancer Res. 2016 Nov 15;22(22):5403-5407. doi: 10.1158/1078-0432.CCR-15-1958. Epub 2016 Sep 21.

12.

The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets.

Wang L, Lonard DM, O'Malley BW.

Horm Cancer. 2016 Aug;7(4):229-35. doi: 10.1007/s12672-016-0261-6. Epub 2016 Apr 28. Review.

13.

Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3.

Song X, Chen J, Zhao M, Zhang C, Yu Y, Lonard DM, Chow DC, Palzkill T, Xu J, O'Malley BW, Wang J.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):4970-5. doi: 10.1073/pnas.1604274113. Epub 2016 Apr 15.

14.

HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.

Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BW.

Cancer Res. 2016 Mar 15;76(6):1463-75. doi: 10.1158/0008-5472.CAN-15-2383. Epub 2016 Feb 1.

15.

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.

Song X, Zhang C, Zhao M, Chen H, Liu X, Chen J, Lonard DM, Qin L, Xu J, Wang X, Li F, O'Malley BW, Wang J.

PLoS One. 2015 Oct 2;10(10):e0140011. doi: 10.1371/journal.pone.0140011. eCollection 2015.

16.

Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death.

Wang L, Yu Y, Chow DC, Yan F, Hsu CC, Stossi F, Mancini MA, Palzkill T, Liao L, Zhou S, Xu J, Lonard DM, O'Malley BW.

Cancer Cell. 2015 Aug 10;28(2):240-52. doi: 10.1016/j.ccell.2015.07.005.

17.

Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.

Ma G, He J, Yu Y, Xu Y, Yu X, Martinez J, Lonard DM, Xu J.

Int J Biol Sci. 2015 Apr 11;11(5):618-28. doi: 10.7150/ijbs.11380. eCollection 2015.

18.

Bufalin is a steroid receptor coactivator inhibitor-response.

Lonard DM, Xu J, O'Malley BW.

Cancer Res. 2015 Mar 15;75(6):1157. doi: 10.1158/0008-5472.CAN-14-2648. Epub 2015 Mar 3. No abstract available.

19.

Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.

Yan F, Yu Y, Chow DC, Palzkill T, Madoux F, Hodder P, Chase P, Griffin PR, O'Malley BW, Lonard DM.

PLoS One. 2014 Apr 17;9(4):e95243. doi: 10.1371/journal.pone.0095243. eCollection 2014.

20.

Steroid receptor coactivator 1 is an integrator of glucose and NAD+/NADH homeostasis.

Motamed M, Rajapakshe KI, Hartig SM, Coarfa C, Moses RE, Lonard DM, O'Malley BW.

Mol Endocrinol. 2014 Mar;28(3):395-405. doi: 10.1210/me.2013-1404. Epub 2014 Jan 17.

21.

Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.

Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, Hodder P, Chase P, Griffin PR, Zhou S, Liao L, Xu J, O'Malley BW.

Cancer Res. 2014 Mar 1;74(5):1506-1517. doi: 10.1158/0008-5472.CAN-13-2939. Epub 2014 Jan 3.

22.

Nuclear receptor coactivators: master regulators of human health and disease.

Dasgupta S, Lonard DM, O'Malley BW.

Annu Rev Med. 2014;65:279-92. doi: 10.1146/annurev-med-051812-145316. Epub 2013 Sep 16. Review.

23.

Proteomic analysis of coregulators bound to ERα on DNA and nucleosomes reveals coregulator dynamics.

Foulds CE, Feng Q, Ding C, Bailey S, Hunsaker TL, Malovannaya A, Hamilton RA, Gates LA, Zhang Z, Li C, Chan D, Bajaj A, Callaway CG, Edwards DP, Lonard DM, Tsai SY, Tsai MJ, Qin J, O'Malley BW.

Mol Cell. 2013 Jul 25;51(2):185-99. doi: 10.1016/j.molcel.2013.06.007. Epub 2013 Jul 11.

24.

Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.

Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW, Mitsiades N.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6997-7002. doi: 10.1073/pnas.1304502110. Epub 2013 Apr 4. Erratum in: Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14386-14387.

25.

SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization.

Yi P, Xia W, Wu RC, Lonard DM, Hung MC, O'Malley BW.

Genes Dev. 2013 Feb 1;27(3):274-87. doi: 10.1101/gad.203760.112.

26.

Nuclear receptor coregulators: modulators of pathology and therapeutic targets.

Lonard DM, O'Malley BW.

Nat Rev Endocrinol. 2012 Oct;8(10):598-604. doi: 10.1038/nrendo.2012.100. Epub 2012 Jun 26. Review.

27.

ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion.

Long W, Foulds CE, Qin J, Liu J, Ding C, Lonard DM, Solis LM, Wistuba II, Qin J, Tsai SY, Tsai MJ, O'Malley BW.

J Clin Invest. 2012 May;122(5):1869-80. doi: 10.1172/JCI61492. Epub 2012 Apr 16.

28.

Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1.

Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, O'Malley BW.

Mol Endocrinol. 2011 Dec;25(12):2041-53. doi: 10.1210/me.2011-1222. Epub 2011 Nov 3.

29.

REGgamma modulates p53 activity by regulating its cellular localization.

Liu J, Yu G, Zhao Y, Zhao D, Wang Y, Wang L, Liu J, Li L, Zeng Y, Dang Y, Wang C, Gao G, Long W, Lonard DM, Qiao S, Tsai MJ, Zhang B, Luo H, Li X.

J Cell Sci. 2010 Dec 1;123(Pt 23):4076-84. doi: 10.1242/jcs.067405.

30.

Comparative analysis of REG{gamma} expression in mouse and human tissues.

Yu G, Zhao Y, He J, Lonard DM, Mao CA, Wang G, Li M, Li X.

J Mol Cell Biol. 2010 Aug;2(4):192-8. doi: 10.1093/jmcb/mjq009. Epub 2010 May 21.

31.

Modulation of steroid hormone receptor activity.

Stanisić V, Lonard DM, O'Malley BW.

Prog Brain Res. 2010;181:153-76. doi: 10.1016/S0079-6123(08)81009-6. Review.

PMID:
20478437
32.

Estrogen receptor-α: molecular mechanisms and interactions with the ubiquitin proteasome system.

Stanišić V, Lonard DM, O'Malley BW.

Horm Mol Biol Clin Investig. 2010 Jan;1(1):1-9. doi: 10.1515/HMBCI.2010.004.

PMID:
25961966
33.

Minireview: the SRC family of coactivators: an entrée to understanding a subset of polygenic diseases?

Lonard DM, Kumar R, O'Malley BW.

Mol Endocrinol. 2010 Feb;24(2):279-85. doi: 10.1210/me.2009-0276. Epub 2009 Oct 21. Review.

34.

OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity.

Stanisić V, Malovannaya A, Qin J, Lonard DM, O'Malley BW.

J Biol Chem. 2009 Jun 12;284(24):16135-45. doi: 10.1074/jbc.M109.007484. Epub 2009 Apr 21.

35.

Emerging roles of the ubiquitin proteasome system in nuclear hormone receptor signaling.

Lonard DM, O'Malley BW.

Prog Mol Biol Transl Sci. 2009;87:117-35. doi: 10.1016/S1877-1173(09)87004-X. Epub 2009 Oct 7. Review.

PMID:
20374703
36.

Multi-modulation of nuclear receptor coactivators through posttranslational modifications.

Han SJ, Lonard DM, O'Malley BW.

Trends Endocrinol Metab. 2009 Jan;20(1):8-15. doi: 10.1016/j.tem.2008.10.001. Epub 2008 Nov 18. Review.

37.

Gene transcription: two worlds merged.

Lonard DM, O'Malley BW.

Nature. 2008 Apr 24;452(7190):946-7. doi: 10.1038/452946a. No abstract available.

PMID:
18432236
38.

SRC-3 transcription-coupled activation, degradation, and the ubiquitin clock: is there enough coactivator to go around in cells?

Lonard DM, O'Malley BW.

Sci Signal. 2008 Apr 1;1(13):pe16. doi: 10.1126/stke.113pe16.

PMID:
18385039
39.

Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1.

Yi P, Feng Q, Amazit L, Lonard DM, Tsai SY, Tsai MJ, O'Malley BW.

Mol Cell. 2008 Feb 29;29(4):465-76. doi: 10.1016/j.molcel.2007.12.030.

40.

A repressive role for prohibitin in estrogen signaling.

He B, Feng Q, Mukherjee A, Lonard DM, DeMayo FJ, Katzenellenbogen BS, Lydon JP, O'Malley BW.

Mol Endocrinol. 2008 Feb;22(2):344-60. Epub 2007 Oct 11.

41.

Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation.

Lonard DM, O'malley BW.

Mol Cell. 2007 Sep 7;27(5):691-700. Review.

42.

Nuclear receptor coregulators and human disease.

Lonard DM, Lanz RB, O'Malley BW.

Endocr Rev. 2007 Aug;28(5):575-87. Epub 2007 Jul 3. Review.

PMID:
17609497
43.

Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway.

Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW.

Mol Cell. 2007 Jun 22;26(6):831-42.

44.

SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock.

Wu RC, Feng Q, Lonard DM, O'Malley BW.

Cell. 2007 Jun 15;129(6):1125-40.

45.

The expanding cosmos of nuclear receptor coactivators.

Lonard DM, O'Malley BW.

Cell. 2006 May 5;125(3):411-4. Review.

46.

The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome.

Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai MJ, O'Malley BW.

Cell. 2006 Jan 27;124(2):381-92.

47.

Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II.

Dennis AP, Lonard DM, Nawaz Z, O'Malley BW.

J Steroid Biochem Mol Biol. 2005 Mar;94(4):337-46.

PMID:
15857753
48.

Expanding functional diversity of the coactivators.

Lonard DM, O'Malley BW.

Trends Biochem Sci. 2005 Mar;30(3):126-32. Review.

PMID:
15752984
49.

A contemporary understanding of progesterone receptor function.

Li X, Lonard DM, O'Malley BW.

Mech Ageing Dev. 2004 Oct-Nov;125(10-11):669-78. Review.

PMID:
15541762

Supplemental Content

Loading ...
Support Center